AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36106308 — intervention group
Group type: EXPERIMENTAL
Intervention: No-charge coronary artery calcium screening
Number of subjects: 36356
Study 36106638 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]-TMP
Number of subjects: 0
Study 36106847 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED + PEN
Number of subjects: 54
Study 36106847 — intervention group
Group type: EXPERIMENTAL
Intervention: EEN
Number of subjects: 54
Study 36106847 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED + PEN or EEN
Number of subjects: 54
Study 36107167 — intervention group
Group type: COMPARATOR
Intervention: Observational study
Number of subjects: 363
Study 36107220 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib 25 mg
Number of subjects: 21
Study 36107220 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 600 mg
Number of subjects: 21
Study 36107221 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMA-CART cell therapy
Number of subjects: 4
Study 36107363 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic beta-blockers
Number of subjects: 249
Study 36107394 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib (45 or 60 mg daily)
Number of subjects: 9
Study 36107411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 222
Study 36107411 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 222
Study 36107473 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention to support physical activity (PA)
Number of subjects: 10
Study 36107482 — intervention group
Group type: EXPERIMENTAL
Intervention: CONEMO digital intervention (18-session psychoeducational program delivered via smartphone app)
Number of subjects: 217
Study 36107482 — intervention group
Group type: EXPERIMENTAL
Intervention: CONEMO digital intervention
Number of subjects: 217
Study 36107483 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment based on genetic analyses of tumor tissue
Number of subjects: 30
Study 36107483 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes (PROs) via dedicated app
Number of subjects: 30
Study 36107585 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation manipulation
Number of subjects: 10
Study 36107585 — intervention group
Group type: COMPARATOR
Intervention: Draining manipulation
Number of subjects: 10
Study 36107703 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fecal microbiome
Number of subjects: 657
Study 36107703 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant fecal microbiome
Number of subjects: 657
Study 36107703 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal gut microenvironment profile
Number of subjects: 657
Study 36107703 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 657
Study 36107810 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening programs for congenital hypothyroidism
Number of subjects: 2
Study 36107810 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic work-up for congenital hypothyroidism
Number of subjects: 2
Study 36108135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation program (home-based respiratory physiotherapy and telephone-based psychological support) consisting of 12 at-home respiratory rehabilitation sessions and 6 telephone-based psychological sessions.
Number of subjects: 108
Study 36108135 — intervention group
Group type: COMPARATOR
Intervention: Usual posthospital care provided by a public Peruvian hospital.
Number of subjects: 108
Study 36108144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial remodeling-based latent class analysis
Number of subjects: 0
Study 36108254 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory approach to expand sustainable COVID-19 testing capacity
Number of subjects: 0
Study 36108256 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rapid antigen COVID-19 testing (BinaxNOW), administered twice weekly for three months.
Number of subjects: 0
Study 36108256 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic testing during the in-home testing program.
Number of subjects: 0
Study 36108256 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home testing program participants opting for symptom testing.
Number of subjects: 0
Study 36108259 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-gene assay (genomic classification)
Number of subjects: 295
Study 36108259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HER2-targeted therapy (trastuzumab plus pertuzumab)
Number of subjects: 295
Study 36108259 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care neoadjuvant chemotherapy with trastuzumab
Number of subjects: 295
Study 36108259 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-gene assay
Number of subjects: 295
Study 36108304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) JZP458 25/25/50 mg/m2 MWF
Number of subjects: 167
Study 36108304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) JZP458 25 mg/m2 MWF
Number of subjects: 167
Study 36108304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) JZP458 37.5 mg/m2 MWF
Number of subjects: 167
Study 36108308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rondaptivon pegol (3 mg on days 0 and 4, then weekly doses of 2 to 9 mg until day 28)
Number of subjects: 19
Study 36108308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rondaptivon pegol (6 doses)
Number of subjects: 19
Study 36108308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rondaptivon pegol
Number of subjects: 19
Study 36108310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 CGM
Number of subjects: 186
Study 36108310 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Libre Pro CGM
Number of subjects: 186
Study 36108334 — intervention group
Group type: EXPERIMENTAL
Intervention: MoveStrong exercise and nutrition program (8-week duration, with 4-week follow-up), including personalized exercise program, 11 remote training sessions, and 3 nutrition education sessions.
Number of subjects: 30
Study 36108341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 55
Study 36108425 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and dexamethasone (Isa-Pd)
Number of subjects: 2
Study 36108425 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 2
Study 36108425 — intervention group
Group type: COMPARATOR
Intervention: Control (pomalidomide and dexamethasone or carfilzomib and dexamethasone)
Number of subjects: 2
Study 36108425 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa)
Number of subjects: 2
Study 36108560 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836880 (40-1000 mg Q3W)
Number of subjects: 53
Study 36108560 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836880 (40-240 mg QW)
Number of subjects: 53
Study 36108594 — intervention group
Group type: EXPERIMENTAL
Intervention: IST + c-Ecu
Number of subjects: 181
Study 36108594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecu + c-IST
Number of subjects: 181
Study 36108594 — intervention group
Group type: COMPARATOR
Intervention: IST alone
Number of subjects: 181
Study 36108661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib (160 mg twice daily)
Number of subjects: 45
Study 36109029 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital exposure treatment
Number of subjects: 0
Study 36109108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative systolic blood pressure (SBP) load
Number of subjects: 9338
Study 36109358 — intervention group
Group type: EXPERIMENTAL
Intervention: rRetrorectus
Number of subjects: 59
Study 36109358 — intervention group
Group type: COMPARATOR
Intervention: IPOM
Number of subjects: 59
Study 36109430 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate drug withdrawal after delivery
Number of subjects: 264
Study 36109430 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed drug withdrawal at 6 weeks after delivery
Number of subjects: 264
Study 36109430 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 264
Study 36109652 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated watermelon rind (MWR) 30 g containing 4 g of L-citrulline
Number of subjects: 11
Study 36109652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 36109693 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Phenotype (FP)
Number of subjects: 44
Study 36109693 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Index (FI)
Number of subjects: 44
Study 36110103 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's FBO membership
Number of subjects: 0
Study 36110103 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's FBO participation
Number of subjects: 0
Study 36110277 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine (acupuncture, Chinese herbs, repeated transcranial magnetic stimulation)
Number of subjects: 202
Study 36110277 — intervention group
Group type: COMPARATOR
Intervention: Standard care (basic treatment, general nursing care, exercise therapy)
Number of subjects: 202
Study 36110295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent PEG-IFNα therapy
Number of subjects: 304
Study 36110295 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment HBsAg response
Number of subjects: 304
Study 36110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic spinal needle with a 27 gauge tip and a 22 gauge shaft
Number of subjects: 326
Study 36110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Research LP procedures
Number of subjects: 326
Study 36110934 — intervention group
Group type: EXPERIMENTAL
Intervention: trabectedin + olaparib
Number of subjects: 0
Study 36110959 — intervention group
Group type: EXPERIMENTAL
Intervention: E150 (150 mg erlotinib for non-smokers)
Number of subjects: 19
Study 36110959 — intervention group
Group type: EXPERIMENTAL
Intervention: E300 (300 mg erlotinib for smokers)
Number of subjects: 19
Study 36110959 — intervention group
Group type: EXPERIMENTAL
Intervention: Early in-treatment [18]FDG PET/CT
Number of subjects: 19
Study 36111056 — intervention group
Group type: EXPERIMENTAL
Intervention: Right thoracic approach (RTA)
Number of subjects: 861
Study 36111056 — intervention group
Group type: COMPARATOR
Intervention: Left thoracic approach (LTA)
Number of subjects: 861
Study 36111149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 0
Study 36111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) long-acting injectable
Number of subjects: 0
Study 36111288 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic (OAP) treatment
Number of subjects: 0
Study 36111611 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video intervention (five versions differing by protagonist gender and race/ethnicity)
Number of subjects: 0
Study 36111801 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR (Fractional Flow Reserve)
Number of subjects: 300
Study 36111801 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 300
Study 36111801 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS (Intravascular Ultrasound)
Number of subjects: 300
Study 36111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferral of revascularization based on iFR
Number of subjects: 300
Study 36111839 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy initiated with a delay (≥8 weeks after surgical resection)
Number of subjects: 101
Study 36111839 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant therapy
Number of subjects: 101
Study 36111839 — intervention group
Group type: COMPARATOR
Intervention: Timely initiation of adjuvant chemotherapy
Number of subjects: 101
Study 36111952 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab (atezo-beva)
Number of subjects: 1244
Study 36111952 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 1244
Study 36111991 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR (Buprenorphine Extended Release)
Number of subjects: 533
Study 36112116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 36112183 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking Olive Leaf Tea
Number of subjects: 0
Study 36112399 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Number of subjects: 814
Study 36112399 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 814
Study 36112541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (Exkivity)
Number of subjects: 114
Study 36112577 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU group
Number of subjects: 178
Study 36112577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not admitted to the ICU
Number of subjects: 178
Study 36112577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had not required mechanical ventilation
Number of subjects: 178
Study 36112577 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 178
Study 36113242 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-159 (12 mg QD)
Number of subjects: 33
Study 36113242 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-159 (≥6 mg QD)
Number of subjects: 33
Study 36113242 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-159
Number of subjects: 33
Study 36113405 — intervention group
Group type: EXPERIMENTAL
Intervention: Family involvement in decision making
Number of subjects: 281
Study 36113405 — intervention group
Group type: COMPARATOR
Intervention: No family involvement
Number of subjects: 281
Study 36113405 — intervention group
Group type: EXPERIMENTAL
Intervention: Family involvement
Number of subjects: 281
Study 36113405 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led or physician-led decision making
Number of subjects: 281
Study 36113405 — intervention group
Group type: COMPARATOR
Intervention: Family-led or family-alone decision making
Number of subjects: 281
Study 36113895 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) followed by intratumoral injection of CD1c (BDCA-1)
Number of subjects: 13
Study 36113946 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational harm reduction approaches
Number of subjects: 500
Study 36113946 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural harm reduction strategies (e.g., syringe service programmes)
Number of subjects: 500
Study 36113946 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Assessment of Provider Harm Reduction Scale (25-item scale)
Number of subjects: 500
Study 36113946 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-centred design approaches
Number of subjects: 500
Study 36113962 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) treatment
Number of subjects: 1977
Study 36113962 — intervention group
Group type: COMPARATOR
Intervention: Not treated with MPA (Control)
Number of subjects: 1977
Study 36113962 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA treatment (adjusted analysis)
Number of subjects: 1977
Study 36114102 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab 300 mg every 2 weeks up to 96 weeks
Number of subjects: 2282
Study 36114184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness levels
Number of subjects: 53
Study 36114405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloplegic biometry (cLP)
Number of subjects: 821
Study 36114405 — intervention group
Group type: COMPARATOR
Intervention: Non-cycloplegic biometry (nLP)
Number of subjects: 821
Study 36114405 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔLP
Number of subjects: 821
Study 36114405 — intervention group
Group type: EXPERIMENTAL
Intervention: |ΔLP|
Number of subjects: 821
Study 36114455 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative AChE activity (U/gHb)
Number of subjects: 127
Study 36114455 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative AChE activity (U/gHb)
Number of subjects: 127
Study 36114495 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TyG index group
Number of subjects: 935
Study 36114495 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index increase
Number of subjects: 935
Study 36114495 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 935
Study 36114723 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise capacity (3-min step test)
Number of subjects: 27
Study 36114723 — intervention group
Group type: COMPARATOR
Intervention: Cough strength (peak expiratory flow meter)
Number of subjects: 27
Study 36114723 — intervention group
Group type: COMPARATOR
Intervention: Thoracoabdominal mobility (upper chest, lower chest, and abdomen)
Number of subjects: 27
Study 36114723 — intervention group
Group type: COMPARATOR
Intervention: Posture (Corbin postural assessment scale)
Number of subjects: 27
Study 36114723 — intervention group
Group type: COMPARATOR
Intervention: Depression (Children's Depression Inventory)
Number of subjects: 27
Study 36114762 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-C subjects
Number of subjects: 0
Study 36114762 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D subjects
Number of subjects: 0
Study 36114762 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-C/CH4+
Number of subjects: 0
Study 36114762 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D
Number of subjects: 0
Study 36114762 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-C/CH4+ subjects
Number of subjects: 0
Study 36115002 — intervention group
Group type: EXPERIMENTAL
Intervention: Spline-based models
Number of subjects: 0
Study 36115002 — intervention group
Group type: COMPARATOR
Intervention: Linear mixed model
Number of subjects: 0
Study 36115665 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to atmospheric pollution (MobiFem project)
Number of subjects: 0
Study 36115665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy lifestyle (EnviFem project)
Number of subjects: 0
Study 36115673 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT (8 Gy × 3 fractions) plus PD-1 inhibitor (tislelizumab) administered in two cycles with a 3-week interval before surgery.
Number of subjects: 20
Study 36115673 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tislelizumab for 1 year after surgery.
Number of subjects: 20
Study 36115674 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL(OT) intervention added to standard multidisciplinary chronic pain treatment
Number of subjects: 40
Study 36115674 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL(OT) intervention
Number of subjects: 40
Study 36115679 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy pregnant women (Cohort A)
Number of subjects: 230
Study 36115679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with suspected sepsis (Cohort B)
Number of subjects: 230
Study 36115679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study (30 pregnant women undergoing elective caesarean section)
Number of subjects: 230
Study 36115679 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine biochemical tests (C reactive protein, lactate, white blood cell count)
Number of subjects: 230
Study 36115679 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic, lipidomic, and metabolomic analyses
Number of subjects: 230
Study 36115679 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and functional immunophenotyping
Number of subjects: 230
Study 36115714 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative pulmonary artery wave reflection
Number of subjects: 27
Study 36115714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery blood flow distribution
Number of subjects: 27
Study 36115714 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular ejection fraction
Number of subjects: 27
Study 36115714 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular ejection fraction and right ventricular strain
Number of subjects: 27
Study 36115931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 combination therapy
Number of subjects: 0
Study 36115947 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 70-140 mg s.c. every 28 days for one year
Number of subjects: 77
Study 36115980 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, L-arginine, and tetrahydrobiopterin
Number of subjects: 10
Study 36116169 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with platinum-etoposide (chemotherapy)
Number of subjects: 86
Study 36116288 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR)
Number of subjects: 33
Study 36116288 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine administration during PLR
Number of subjects: 33
Study 36116293 — intervention group
Group type: EXPERIMENTAL
Intervention: remedē System Therapy (transvenous phrenic nerve stimulation)
Number of subjects: 500
Study 36116359 — intervention group
Group type: EXPERIMENTAL
Intervention: CARMELINA (n = 2666)
Number of subjects: 6962
Study 36116359 — intervention group
Group type: EXPERIMENTAL
Intervention: CAROLINA (n = 4296)
Number of subjects: 6962
Study 36116359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 6962
Study 36116420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg intravenously
Number of subjects: 151
Study 36116506 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CEL IgG and IgA antibodies in patients with HS
Number of subjects: 0
Study 36116506 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CEL IgG (IgG2 subclass)
Number of subjects: 0
Study 36116506 — intervention group
Group type: EXPERIMENTAL
Intervention: CEL and anti-CEL producing plasmablasts
Number of subjects: 0
Study 36116543 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made decompression appliance fabricated using a digital workflow
Number of subjects: 6
Study 36116752 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hepatitis B virus (aHBV) infection
Number of subjects: 60
Study 36116752 — intervention group
Group type: COMPARATOR
Intervention: Chronic hepatitis B virus (cHBV) untreated controls
Number of subjects: 60
Study 36116866 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 283